Our results showed that a minimum expression of TGF-β and α-SMA in the normal breast tissue (n=10), while they were obviously increased in tumor tissues (n=121), especially from the samples of patients with clinical stage III/IV breast cancer (Figure 1). The gene discussed is ACTA1; the disease is breast carcinoma.